Bayer Halts Sales Of Trasylol

FRANKFURT, GERMANY - Bayer AG announced today that it is stopping worldwide sales of Trasylol, used to reduce bleeding, because a Canadian clinical study found use of the drug could increase risk of death. Trasylol is an aprotinin, which blocks enzymes that dissolve blood clots. In October, the U.S. FDA allowed Trasylol to remain on the market despite studies that showed increased risk of death and other side effects.

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Email *

Submit